Những podcast Lancet Oncology hay nhất (2024)

1
In conversation with... Bernardo Goulart 11:22

15d ago11:22

11:22

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.Bởi The Lancet

1
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials 11:22

16d ago11:22

11:22

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_…

1
In conversation with... Maria Kyrgiou 25:42

2M ago25:42

25:42

In a special episode on International Women's Day 2024, we speak with Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.Bởi The Lancet

1
Maria Kyrgiou on innovations in gynaecological cancers and global disparities 25:42

2M ago25:42

25:42

In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.co…

1
In conversation with... Georgios Lyratzopoulos 34:43

2M ago34:43

34:43

Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia.Bởi The Lancet

1
Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers 34:43

2M ago34:43

34:43

Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & htt…

1
In conversation with... Mike Sathekge 16:06

3M ago16:06

16:06

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’Bởi The Lancet

1
Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer 16:06

3M ago16:06

16:06

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’ Read the full article: https://www.thelancet.com/journals/lanonc/article/…

1
Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma 13:53

4M ago13:53

13:53

Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma. Continue this conversation on social! Follow us today at... h…

1
In conversation with... Shankar Siva 13:53

4M ago13:53

13:53

Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.Bởi The Lancet

1
Neerja Bhatla on a new quadrivalent HPV vaccine 12:24

5M ago12:24

12:24

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India. Read the full article: https://www.thelancet.com/journals/la…

1
In conversation with... Neerja Bhatla 12:24

5M ago12:24

12:24

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.Bởi The Lancet

1
Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery 43:49

6M ago43:49

43:49

Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldwide. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.co…

1
In conversation with... Chandra Are 43:49

6M ago43:49

43:49

Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.Bởi The Lancet

1
In conversation with... Philipp Karschnia 17:10

6M ago17:10

17:10

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.Bởi The Lancet

1
Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma 17:10

6M ago17:10

17:10

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma. Read the full Policy Review: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2…

1
In conversation with... Wanda Cui

7M ago

—

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.Bởi The Lancet

1
Wanda Cui on measuring ovarian toxicity 10:37

7M ago10:37

10:37

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Continue this conversation o…

1
Ticiana Leal on Tumour Treating Fields 9:01

8M ago9:01

9:01

Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00344-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Continue this conversation on social! Follow us today at... https://twitte…

1
In conversation with... Ticiana Leal 9:01

8M ago9:01

9:01

Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.Bởi The Lancet

1
In conversation with... Xuesong Han 12:31

9M ago12:31

12:31

Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.Bởi The Lancet

1
Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA 12:31

9M ago12:31

12:31

Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00293-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Continue t…

1
Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma 33:50

10M ago33:50

33:50

Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00246-2/fulltext?dgcid…

1
In conversation with... Carlos Fernández de Larrea and Damian Green 33:50

10M ago33:50

33:50

Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.Bởi The Lancet

1
In conversation with... Madeline Pe 14:01

11M ago14:01

14:01

Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.Bởi The Lancet

1
Madeline Pe on the SISAQOL initiative 14:01

11M ago14:01

14:01

Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative. Read the full article: https://www.thelancet.com/journals/lanonc/article/P…

1
In conversation with... Kadia Petricca and Joyce Kambugu 28:40

12M ago28:40

28:40

Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”.…

1
Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children 28:40

12M ago28:40

28:40

Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”. Read the full…

1
In Conversation With... Mark Lythgoe 14:11

1y ago14:11

14:11

Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".Bởi The Lancet

1
Mark Lythgoe on UK oncology drug approval after Brexit 14:11

1y ago14:11

14:11

Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit". Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol…

1
In conversation with... Janet Brown 20:43

1y ago20:43

20:43

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.Bởi The Lancet

1
Janet Brown on the phase 2/3 STAR trial 20:43

1y ago20:43

20:43

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma. Read the full article: Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cel…

1
Valerie Speirs on biomarkers in male breast cancer 17:40

1y ago17:40

17:40

Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer. Read the full article: Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cance…

1
In conversation with... Valerie Speirs 17:40

1y ago17:40

17:40

Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer.Bởi The Lancet

1
In conversation with... Sameer Bakhshi 23:02

1+ y ago23:02

23:02

Prof Sameer Bakhshi, (All India Institute of Medical Sciences, New Delhi, India) discusses his Article on sex disparities in childhood cancer in India.Bởi The Lancet

1
Sameer Bakhshi on sex disparities in childhood cancer in India 23:02

1+ y ago23:02

23:02

Prof Sameer Bakhshi, (All India Institute of Medical Sciences, New Delhi, India) discusses his Article on sex disparities in childhood cancer in India. Read the full article: Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis Continue this conversation on social! Follow us today at... https://twitter.com/th…

1
Shankar Siva on radiotherapy for primary renal cell carcinoma 8:30

1+ y ago8:30

8:30

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma. Read the full article: 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma Continue this conversation on social! Follow…

1
In conversation with... Shankar Siva 8:30

1+ y ago8:30

8:30

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.Bởi The Lancet

1
Mark Lawler and Richard Sullivan on the European Groundshot 23:20

1+ y ago23:20

23:20

Mark Lawler (Queen’s University Belfast, Belfast, UK) and Richard Sullivan (Kings College London, London, UK) discuss the European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol htt…

1
In conversation with... Mark Lawler and Richard Sullivan 23:20

1+ y ago23:20

23:20

Mark Lawler (Queen’s University Belfast, Belfast, UK) and Richard Sullivan (Kings College London, London, UK) discuss the European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission.Bởi The Lancet

1
In conversation with... Samar Alhomoud 10:33

1+ y ago10:33

10:33

Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council.Bởi The Lancet

1
Samar Alhomoud on challenges for cancer control in the Gulf region 11:27

1+ y ago11:27

11:27

Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council. Read the full article: Progress and remaining challenges for cancer control in the Gulf Cooperation Council Continue this conversation on social! Fol…

1
Inge Marie Svane on mRNA vaccines for cancer treatment 8:11

1+ y ago8:11

8:11

Inge Marie Svane (Copenhagen University Hospital, Copenhagen, Denmark) discusses her Review on clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Read the full Review: Clinical advances and ongoing trials on mRNA vaccines for cancer treatment Continue this conversation on social! Follow us today at... https://twitter.com/th…

1
In conversation with... Inge Marie Svane 8:11

1+ y ago8:11

8:11

Inge Marie Svane (Copenhagen University Hospital, Copenhagen, Denmark) discusses her Review on clinical advances and ongoing trials on mRNA vaccines for cancer treatment.Bởi The Lancet

1
In conversation with... Eline Giraud and Elise Smolders 11:39

1+ y ago11:39

11:39

Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs.Bởi The Lancet

1
Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer 11:39

1+ y ago11:39

11:39

Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs. Read the full Review: The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview Continue this conversation on soc…

1
Ignace Vergote and Maria Kyrgiou on gynaecological cancers 10:30

1+ y ago10:30

10:30

Ignace Vergote (Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium) and Maria Kyrgiou (Imperial College London, London, UK) discuss their Series papers on gynaecological cancers. Visit the Series hub: Gynaecological cancers Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter…

1
In conversation with... Ignace Vergote and Maria Kyrgiou 10:30

1+ y ago10:30

10:30

Ignace Vergote (Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium) and Maria Kyrgiou (Imperial College London, London, UK) discuss their Series papers on gynaecological cancers.Bởi The Lancet

1
In conversation with... David J Pinato 5:19

2y ago5:19

5:19

David J Pinato (Imperial College London, London, UK) discusses the OnCovid registry study on the outcomes of the SARS-CoV-2 omicron variant outbreak among patients with cancer in Europe.Bởi The Lancet

1
David J Pinato on SARS-CoV-2 omicron outcomes among patients with cancer 5:19

2y ago5:19

5:19

David J Pinato (Imperial College London, London, UK) discusses the OnCovid registry study on the outcomes of the SARS-CoV-2 omicron variant outbreak among patients with cancer in Europe. Read the full article: Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe Continue th…

Podcast đáng để nghe

Podcast Lancet Oncology

Podcast đáng để nghe

Hướng dẫn sử dụng nhanh